- The US Patent and Trademark Office’s patent issuance marks the first patent issuance to Aclipse for M102’s four patent families.
- M102 is in preclinical development for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
- M102 is financially supported by the United States Department of Defense, the United Kingdom’s Medical Research Council, and Australia’s FightMND.
Radnor, PA, USA – November 10, 2022 – Aclipse Therapeutics, and its subsidiary Aclipse One, Inc (“Aclipse” or “the Company”), an innovative biopharmaceutical company developing life-changing treatments for patients with severe diseases, announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent no. 11,459,301 entitled, “Crystalline Form of S-Apomorphine”. The patent protects the composition-of-matter of the Company’s M102 drug candidate as well as the related methods of use, with expected patent protection to at least 2039.
Aclipse is conducting IND-enabling studies for M102 for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig’s disease. M102 takes a dual mechanism approach to the treatment of ALS with M102 activating both the Nrf2 (nuclear factor erythroid 2-related factor 2) and HSF1 (Heat shock factor 1) signaling pathways. The Company is taking a targeted, precision approach to the development of M102 by identifying genetic markers of potential ALS drug responders. Industry data indicates that a precision medicine approach increases the probability of clinical success by 2- to 3-fold.
Aclipse licensed M102 from the Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield, United Kingdom and is developing M102 with Professor Dame Pamela Shaw, MD and her team at SITraN with support from the United Kingdom’s Medical Research Council, Australia’s FightMND, and the United States Department of Defense through its U.S. Army Medical Research and Development Command.
“This patent issuance is an important step in the development of M102 for use in ALS patients who are in urgent need of effective therapies. Based on preclinical results to date, M102 may be mechanistically superior to currently approved ALS drugs and may lead to significant slowing of disease progression in patients with ALS with potential impact in other neurodegenerative diseases,”
stated Raymond K. Houck, Chief Executive Officer of Aclipse Therapeutics.
About ALS/MND
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects motor neurons (nerve cells) in the brain and the spinal cord. Eventually, people with ALS lose the ability to initiate and control muscle movement, which often leads to total paralysis and death within two to five years of diagnosis. Based on population studies, as many as 25,000 Americans have ALS at any given time.
About Aclipse Therapeutics
Aclipse Therapeutics is an innovative biopharmaceutical company that develops novel and differentiated drugs to treat diseases with significant unmet medical needs. M102 is a dual Nrf2/HSF1 activator for the treatment of ALS and other neurodegenerative diseases. M102 uses a precision medicine approach to identify those ALS patients who are most likely to benefit from the drug. Aclipse has an experienced drug development team and a clinical advisory board of key opinion leaders in ALS. For more information about Aclipse Therapeutics, visit the website at https://www.aclipsetherapeutics.com or email info@aclipsetherapeutics.com.
Contact:
Raymond K. Houck
rhouck@aclipsetherapeutics.com
+1-412-606-7214